Jennison Associates’s Monte Rosa Therapeutics GLUE Stock Holding History

Jennison Associates’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-530,065	Closed	-$10.8M	–	662
2021 Q4	$10.8M	Buy	530,065 +233,686	+79%	+$4.89M	0.01%	439
2021 Q3	$6.6M	Sell	296,379 -3,621	-1%	-$104K	﹤0.01%	475
2021 Q2	$6.81M	Buy	+300,000	New	+$6.11M	﹤0.01%	483

Other funds holding GLUE

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Jennison Associates's GLUE Position: Q1 2022 in Review

Jennison Associates sold out of Monte Rosa Therapeutics (GLUE) in Q1 2022, closing a stake of 530,065 shares — an estimated $10.8M sold.

Jennison Associates first reported a position in GLUE in Q2 2021 and held it in 3 quarters. The position peaked at $10.8M in Q4 2021. 52 funds tracked by Wall St. Rank hold GLUE as of Q1 2022.

Jennison Associates reported no remaining Monte Rosa Therapeutics position as of Q1 2022 after selling out during the quarter.
Jennison Associates sold 530,065 Monte Rosa Therapeutics shares in Q1 2022, an estimated $10.8M.
Jennison Associates first reported a position in Monte Rosa Therapeutics in Q2 2021 and held it in 3 quarters.
Jennison Associates's Monte Rosa Therapeutics position peaked at $10.8M in Q4 2021.
52 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q1 2022.

Based on Jennison Associates's 13F filing for Q1 2022, filed 11 May 2022.